“…They aim at applying to SCD the model already in use with other rare and complex disorders of childhood such as cystic fibrosis and hemophilia for which a similar model has granted patients with those diseases, good quality care, and an improved survival with better quality of life. 1 In fact, as the authors note, in spite of the scientific advancements and the isolated National Sickle Cell Disease Control Act, in the past 30 years the limited funding and investments for SCD have resulted in reduced access to comprehensive care, lack of improvement of the estimated median survival-which remained more or less the same in the past 20 years-and lack of development of implementation research.…”